Document:

CareView Communications, Inc. 8-K

 

Exhibit 10.43

 

NINTH
AMENDMENT TO

NOTE AND WARRANT PURCHASE AGREEMENT

This NINTH AMENDMENT
TO NOTE AND WARRANT PURCHASE AGREEMENT, dated as of July 10, 2018 (this “Amendment”), is made by and among
CAREVIEW COMMUNICATIONS, INC., a Nevada corporation (the “Company”), the HealthCor Parties (as defined
below), and the other holders of Notes identified on the signature pages hereto (collectively with the HealthCor Parties, and together
with their respective successors and permitted assigns, the “Investors”).

WITNESSETH:

WHEREAS, the
Company, HealthCor Partners Fund, L.P. (“HealthCor Partners”), HealthCor Hybrid Offshore Master Fund, L.P. (“HealthCor
Hybrid” and, together with HealthCor Partners, the “HealthCor Parties”) and certain additional investors
that purchased additional Notes and additional Warrants on February 17, 2015 (the “2015 Investors”) and on February
23, 2018 (the “2018 Investors”) are parties to that certain Note and Warrant Purchase Agreement, dated as of
April 21, 2011 (as amended from time to time, including without limitation pursuant to that certain Note and Warrant Amendment
Agreement dated December 30, 2011, that certain Second Amendment to Note and Warrant Purchase Agreement dated January 31, 2012,
that certain Third Amendment to Note and Warrant Purchase Agreement dated August 20, 2013, that certain Fourth Amendment to Note
and Warrant Purchase Agreement dated January 16, 2014, that certain Fifth Amendment to Note and Warrant Purchase Agreement dated
December 15, 2014, that certain Sixth Amendment to Note and Warrant Purchase Agreement dated March 31, 2015, that certain Seventh
Amendment to Note and Warrant Purchase Agreement dated June 26, 2015, and that certain Eighth Amendment to Note and Warrant Purchase
Agreement dated February 23, 2018, the “Purchase Agreement”);

WHEREAS, as
contemplated by the Purchase Agreement, the Company issued and sold (a) $20,000,000 initial principal amount of Notes (the “2011
Notes”) and Warrants to purchase 11,782,859 shares of Common Stock (the “2011 Warrants”) to the HealthCor
Parties on April 21, 2011, (b) $5,000,000 initial principal amount of Supplemental Closing Notes (the “2012 Notes”)
to the HealthCor Parties on January 31, 2012, (c) $5,000,000 initial principal amount of 2014 Supplemental Closing Notes and
2014 Supplemental Warrants to purchase 4,000,000 shares of Common Stock to the HealthCor Parties on January 16, 2014, (d) $6,000,000
initial principal amount of Fifth Amendment Supplemental Closing Notes and Fifth Amendment Supplemental Warrants to purchase 3,692,308
shares of Common Stock to HealthCor Partners and the 2015 Investors on February 17, 2015 and (e) $2,050,000 initial principal amount
of Eighth Amendment Supplemental Notes and Eighth Amendment Supplemental Warrants to purchase 512,500 shares of Common Stock to
the 2018 Investors on February 23, 2018; and

WHEREAS, pursuant
to Section 7.9 of the Purchase Agreement and subject to the terms and conditions contained herein, the parties hereto desire to
amend the Purchase Agreement and the Notes and certain ancillary documents as set forth herein for the purposes of, among other
things, (a) removing the conversion rights of the 2011 Notes and the 2012 Notes, suspending the accrual of interest thereon for
periods after June 30, 2018, and providing for the potential earlier repayment thereof subject to certain conditions, including
the Company’s senior debt being repaid in full, being first met; (b) cancelling the Warrants issued to the HealthCor
Parties on April 21, 2011; (c) providing for the seniority of the 2011 Notes and the 2012 Notes in right of payment over subsequently
issued additional Notes, on the terms outlined in this Amendment; (d) amending the terms of the 2014 Supplemental Closing Notes,
the Fifth Amendment Supplemental Closing Notes and the Eighth Amendment Supplemental Closing Notes to reflect the seniority in
payment of the 2011 Notes and 2012 Notes; and (e) reducing the number of shares of Common Stock that the Company must at all
times have authorized and reserved for the purpose of issuance upon conversion of the Notes and exercise of the Warrants, from
at least 120% of the aggregate number of shares of Common Stock then issuable upon full conversion of the Notes and exercise of
the Warrants to at least 100% of such aggregate number of shares.

    	 		 

    	 

    

NOW, THEREFORE,
in consideration of the mutual promises, representations, warranties and covenants contained herein and in the Purchase Agreement,
which represent integral components of the transactions contemplated hereby and thereby and shall be fully enforceable by the parties
hereto, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company
and the Investors mutually agree as follows:

1.       

Definitions. Capitalized terms used
in this Amendment but not defined in this Amendment shall have the meanings ascribed to them in the Purchase Agreement.

2.       

Amendment to Purchase Agreement.
Section 5.8 of the Purchase Agreement is hereby amended and restated in its entirety to read as follows:

“Reservation of Shares.
The Company shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, not less
than 100% of the number of shares of Common Stock issuable upon full conversion of the Notes and exercise of the Warrants (the
“Required Reserve Amount”). If at any time while any Note and/or Warrant remains outstanding the Company does
not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve the Required
Reserve Amount (an “Authorized Share Failure”), then the Company shall take all action necessary to increase
the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve
Amount. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an
Authorized Share Failure, but in no event later than seventy-five (75) days after the occurrence of such Authorized Share Failure,
the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common
Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its commercially
reasonable efforts to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause
its board of directors to recommend to the stockholders that they approve such proposal.”

3.       

Payment Subordination.

(a)       

Definitions. As used in this section,
the following terms shall have the following meanings:

“Bankruptcy
Code” means Title 11 of the United States Code entitled “Bankruptcy,” as now and hereafter in effect, or
any successor statute.

“Debtor Relief
Laws” means the Bankruptcy Code, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of
creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States
or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.

“Disposition”
means any sale, lease, exchange, transfer or other disposition of any Collateral.

“Grantor”
has the meaning set forth in the Security Agreement.

“Insolvency
or Liquidation Proceeding” means:

(i)       

any voluntary or involuntary
case or proceeding under the Bankruptcy Code with respect to the Borrower, Holdings or any Grantor;

    	 	2	 

    	 

    

(ii)       

any other voluntary
or involuntary insolvency, reorganization or bankruptcy case or proceeding, or any receivership, liquidation, reorganization or
other similar case or proceeding, with respect to the Borrower, Holdings or any Grantor or with respect to a material portion of
its assets;

(iii)       

any liquidation, dissolution,
reorganization or winding up of the Borrower, Holdings or any Grantor, whether voluntary or involuntary and whether or not involving
insolvency or bankruptcy; or

(iv)       

any assignment for
the benefit of creditors or any other marshaling of assets and liabilities of the Borrower, Holdings or any Grantor.

(b)       

Each Investor covenants and agrees, notwithstanding
anything to the contrary contained in the Purchase Agreement or any of the Notes, that the payment of any and all principal, interest
and other obligations under the Notes issued subsequent to the 2011 Notes and 2012 Notes (collectively, the “Subsequent
Tranche Notes”) shall be subordinate and subject in right and time of payment, to the extent and in the manner hereinafter
set forth, to the payment in full in cash of all principal, interest and other obligations under the 2011 Notes and 2012 Notes
(collectively, the “First Tranche Notes”). Until the date all principal, interest and other obligations in respect
of the First Tranche Notes have been paid in full in cash, except as set forth in Section 3(c), no Investor holding Subsequent
Tranche Notes shall accept any distribution, whether in cash, securities or other property, on account of any obligations under
the Subsequent Tranche Notes. For the avoidance of doubt, the “Subsequent Tranche Notes” include each of the 2014 Supplemental
Closing Notes, the Fifth Amendment Supplemental Closing Notes, the Eighth Amendment Supplemental Closing Notes, and any additional
Notes issued under the Purchase Agreement, as it may be amended from time to time, after the date of this Amendment.

(c)       

Notwithstanding Section 3(b) of
this Amendment, the Investors holding Subsequent Tranche Notes may receive and retain the following distributions in respect of
the Subsequent Tranche Notes: (i) payment of interest in kind that is capitalized and added to the outstanding principal amount
of the Subsequent Tranche Notes in accordance with the terms thereof as in effect as of the date hereof and (ii) the conversion
of the Subsequent Tranche Notes into equity securities of the Company.

(d)       

Until the payment in full in cash of any
and all principal, interest and other obligations under the First Tranche Notes, whether or not any Insolvency or Liquidation Proceeding
has been commenced by or against the Company or any other Grantor, any payment received by any Investor in respect of the Subsequent
Tranche Notes in contravention of this Amendment shall be segregated and held in trust and forthwith paid over to HealthCor Partners
as the collateral agent, for the benefit of the Investors holding First Tranche Notes in the same form as received, with any necessary
endorsements or as a court of competent jurisdiction may otherwise direct. HealthCor Partners, as the collateral agent, is hereby
authorized to make any such endorsements as agent for any Investors. This authorization is coupled with an interest and is irrevocable
until the payment in full in cash of any and all principal, interest and other obligations under the First Tranche Notes.

4.       

Exercise of Remedies.

(a)       

Until all principal, interest and other
obligations under the First Tranche Notes have been paid in full in cash:

(i)       

(1) except for non-cash payments permitted
by Section 3(c) of this Amendment, the Investors holding Subsequent Tranche Notes will not take from or for the account
of the Company or any other Grantor, by set-off or in any other manner, the whole or any part of any moneys which may now or hereafter
be owing by the Company or any other Grantor with respect to the obligations under the Subsequent Tranche Notes; (2) will not sue
for payment of, or initiate or participate with others in any suit, action or proceeding against the Company or any other Grantor
to (x) enforce payment of or collect the whole or any part of the obligations under the Subsequent Tranche Notes (which shall include,
for the avoidance of doubt, any demand or collection of payment at maturity), or (y) commence judicial enforcement of any of the
rights and remedies under the Transaction Documents or applicable law with respect to the obligations under the Subsequent Tranche
Notes; and (3) will not exercise any put option or cause the Company or any other Grantor to honor any redemption or mandatory
prepayment obligation under any Transaction Document with respect to the obligations under the Subsequent Tranche Notes;

    	 	3	 

    	 

    

(ii)       

will not exercise or seek to exercise any
remedies with respect to any Lien on any Collateral (as defined in the Security Agreement) to secure the performance of the obligations
under the Subsequent Tranche Notes or institute any action or proceeding with respect to such remedies (including any action of
foreclosure);

(iii)       

will not contest, protest, object to, or
take any action to hinder or delay (including taking action to commence an involuntary Insolvency or Liquidation Proceeding) any
foreclosure proceeding or action brought by the Investors holding First Tranche Notes or any other exercise by Investors holding
First Tranche Notes of any rights and remedies relating to the Collateral securing the obligations under the First Tranche Notes;
and

(iv)       

will not object to the forbearance by the
Investors holding First Tranche Notes from bringing or pursuing any foreclosure proceeding or action or any other exercise of any
rights or remedies relating to the Collateral;

provided, that, in the case of clause
(iii) above, the security interests granted to secure the obligations under the Subsequent Tranche Notes shall attach to any remaining
proceeds resulting from actions taken by the holders of the First Tranche Notes in accordance with this Amendment after application
of such proceeds to pay in full in cash any and all principal, interest and other obligations under the First Tranche Notes.

(b)       

Until the payment in full in cash of all
principal, interest and other obligations under the First Tranche Notes has occurred, whether or not any Insolvency or Liquidation
Proceeding has been commenced by or against the Company or any Grantor, the Investors holding First Tranche Notes shall have the
right to enforce rights, exercise remedies (including set off and the right to credit bid their debt) and make determinations regarding
the release, Disposition, or restrictions with respect to the Collateral without any consultation with or the consent of any holder
of Subsequent Tranche Notes; provided, that the Lien securing the obligations under the Subsequent Tranche Notes shall remain on
the remaining proceeds of such Collateral released or disposed of subject to the relative priorities described in Section 3
after application of such proceeds to the extent necessary to effect the payment in full in cash of all principal, interest and
other obligations under the First Tranche Notes. In exercising rights and remedies with respect to the Collateral, the Holders
of First Tranche Notes may enforce the provisions of the Transaction Documents and exercise remedies thereunder, all in such order
and in such manner as they may determine in the exercise of their sole discretion. Such exercise and enforcement shall include
the rights of any agent appointed by them to sell or otherwise dispose of Collateral upon foreclosure, to incur expenses in connection
with such sale or disposition and to exercise all the rights and remedies of a secured creditor under the UCC (as defined in the
Security Agreement) and of a secured creditor under the Debtor Relief Laws of any applicable jurisdiction. In furtherance of the
foregoing, and for avoidance of doubt, until the payment in full in cash of all principal, interest and other obligations under
the First Tranche Notes has occurred, the term “Required Secured Parties” set forth in the Security Agreement shall
be deemed to mean the holders of more than 50% of the aggregate outstanding principal balance of the First Tranche Notes.

5.       

Hospital Disposition. In connection
with any Hospital Disposition, as such term is defined in the PDL Subordination Agreement, the Company agrees to use the net proceeds
thereof, after payment of transaction expenses, first, to repay the Company’s obligations under the PDL Credit Agreement
until such obligations are paid in full; and second, to apply the remaining net proceeds (less up to $5,000,000 which the
Company may retain for working capital purposes) to repayment of the outstanding Principal and Interest on the Notes, until such
amounts are repaid in full. If the proceeds of any such Hospital Disposition are insufficient to repay the Company’s obligations
under the PDL Credit Agreement in full, the Company undertakes to the HealthCor Parties that it will use its commercially reasonable
efforts to repay any remaining obligations under the PDL Credit Agreement as soon as practicable, including without limitation
with cash from operations.

6.       

Cancellation of 2011 Warrants. The
Company and the HealthCor Parties hereby agree that the 2011 Warrants, issued to the HealthCor Parties and dated April 21, 2011,
representing the right to purchase an aggregate of 11,782,859 shares of Common Stock, are hereby cancelled and shall be of no further
force and effect.

    	 	4	 

    	 

    

7.       

Conditions Precedent. The transactions
contemplated by this Amendment shall be conditioned upon the satisfaction of the following conditions:

(a)       

The execution and delivery by the Company
and the HealthCor Parties of Allonge No. 2 to the 2011 Notes and Allonge No. 2 to the 2012 Notes, in the forms attached as Exhibits
7(a)(1) and 7(a)(2) hereto, respectively;

(b)       

The execution and delivery by the Company
and each holder of the 2014 Supplemental Closing Notes of Allonge No. 2 to the 2014 Supplemental Closing Notes, in the form attached
as Exhibit 7(b) hereto;

(c)       

The execution and delivery by the Company
and each holder of the Fifth Amendment Supplemental Closing Notes of Allonge No. 2 to the Fifth Amendment Supplemental Closing
Notes, in the form attached as Exhibit 7(c) hereto;

(d)       

The execution and delivery by the Company
and each holder of the Eighth Amendment Supplemental Closing Notes of Allonge No. 1 to the Eighth Amendment Supplemental Closing
Notes, in the form attached as Exhibit 7(d) hereto; and

(e)       

The execution and delivery by the Company,
CareView Texas, PDL and the Investors of the Second Amendment to Subordination and Intercreditor Agreement, in the form attached
as Exhibit 7(e) hereto.

8.       

Acknowledgement and Undertaking by Company.
The Company agrees and acknowledges that the transactions described in this Amendment, including without limitation the cancellation
of the 2011 Warrants, are intended to be exempt from Section 16(b) of the Exchange Act to the maximum extent permitted by law including
pursuant to Rule 16b-3 under the Exchange Act and the Commission’s releases and interpretations, and will, or will cause
its successors and assigns to, from time to time as and when requested by the Investors, execute and deliver, or cause to be executed
and delivered, to the extent it may lawfully do so, all such documents and instruments and take, or cause to be taken, to the extent
it may lawfully do so, all such further actions as the Investors may reasonably deem necessary and desirable to facilitate and
effect any such exemption. 

9.       

No Further Amendments. Except as
amended by this Amendment, the Purchase Agreement shall remain in full force and effect in accordance with its terms.

10.       

Miscellaneous.

(a)       

Ratification and Confirmation.
The Company acknowledges, agrees and confirms that: (x) the Purchase Agreement and each of the other Transaction Documents, as
amended and otherwise modified by the amendments and other modifications specifically provided herein or contemplated hereby, are
and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed; and (y) without limiting
the generality of the foregoing clause (x), all obligations, liabilities and Indebtedness of the Company under the Transaction
Documents, as amended hereby, constitute “Obligations” (as defined in the Security Agreement) secured by and entitled
to the benefits of the security set forth in the Security Agreement and the IP Security Agreement, and the liens and security interests
granted in favor of the Investors under the terms of the Security Agreement and the IP Security Agreement are and remain perfected,
effective, enforceable and valid and such liens and security interests are, in each case, a first priority lien and security interest
(except to the extent otherwise expressly permitted by the Transaction Documents) and such liens and security interests are hereby
in all respects ratified and confirmed.

(b)       

Expenses. The Company will pay
and bear full responsibility for the reasonable legal fees and other out-of-pocket costs and expenses of the Investors attributable
to the negotiation and consummation of the transactions contemplated hereby.

    	 	5	 

    	 

    

(c)       

Further Assurances. The Company
shall duly execute and deliver, or cause to be duly executed and delivered, at its own cost and expense, such further instruments
and documents and to take all such action, in each case as may be necessary or proper in the reasonable judgment of the Investors
to carry out the provisions and purposes of this Amendment.

(d)       

Survival. The representations,
warranties, covenants and agreements made herein shall survive any investigation made by any party hereto, the execution and delivery
of this Amendment and the closing of the transactions contemplated hereby.

(e)       

Governing Law. All questions concerning
the construction, interpretation and validity of this Amendment shall be governed by and construed and enforced in accordance with
the domestic laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether in
the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the
State of Delaware. In furtherance of the foregoing, the internal law of the State of Delaware will control the interpretation and
construction of this Amendment, even if under such jurisdiction’s choice of law or conflict of law analysis, the substantive
law of some other jurisdiction would ordinarily or necessarily apply.

(f)       

Construction. The Company and the
Investors acknowledge that the Company and its independent counsel and the Investors and their independent counsel have jointly
reviewed and drafted this document, and agree that any rule of construction and interpretation to the effect that drafting ambiguities
are to be resolved against the drafting party shall not be employed.

(g)       

Counterparts; Facsimile and Electronic
Signatures. This Amendment may be executed in any number of counterparts, and each such counterpart hereof shall be deemed
to be an original instrument, but all such counterparts together shall constitute but one agreement. Counterpart signatures to
this Amendment delivered by facsimile or other electronic transmission shall be acceptable and binding.

(h)       

Headings. The section and paragraph
headings contained in this Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation
of this Amendment.

[Signature Pages Follow]

    	 	6	 

    	 

    

IN WITNESS WHEREOF,
each of the undersigned has duly executed this Ninth Amendment to Note and Warrant Purchase Agreement as of the date first written
above.

 

	 	COMPANY:
	 	 	 
	 	CareView Communications, Inc., a Nevada corporation
	 	 	 
	 	By:	/s/ Steven G. Johnson
	 	Name: 	Steven G. Johnson
	 	Title: 	President

 

 

 

	 	INVESTORS:
	 	 	 
	 	HealthCor Partners Fund, L.P.
	 	By:   HealthCor Partners Management L.P., as Manager
	 	By:   HealthCor Partners Management, G.P., LLC, as General Partner
	 	 	 
	 	By:	/s/ Jeffrey C. Lightcap
	 	Name: 	Jeffrey C. Lightcap
	 	Title: 	Senior Managing Director

 

	 	Address:	HealthCor Partners
	 	 	1325 Avenue of Americas, 27th Floor
	 	 	New York, NY 10019
	 	 	 

 

	 	HealthCor Hybrid Offshore Master Fund, L.P.
	 	By: HealthCor Hybrid Offshore G.P., LLC, as General Partner
	 	 	 
	 	By:	 /s/ Joseph P. Healey
	 	Name: 	Joseph P. Healey
	 	Title: 	Trustee

	 	Address:	HealthCor Partners
	 	 	1325 Avenue of Americas, 27th Floor
	 	 	New York, NY 10019
	 	 	 

 

 

[Signature Page to Ninth Amendment to Note and
Warrant Purchase Agreement]

 

    	 

    	 

    

	 	INVESTORS:
	 	 
	 	/s/ Allen Wheeler
	 	Allen Wheeler
	 	 
	 	/s/ Steven Johnson
	 	Steven Johnson
	 	 
	 	/s/ Dr. James R. Higgins
	 	Dr. James R. Higgins

 

 

 

[Signature Page to Ninth Amendment to Note and
Warrant Purchase Agreement]

 

    	 

    	 

    

	 	INVESTORS:
	 	 
	 	Raymond James & Assoc. Inc., not in its corporate capacity but solely as Custodian of the Individual Retirement Account of Sandra K. McRee.  Further, all representations, warranties and covenants (including indemnities) set forth herein are being made by Sandra K. McRee, not Raymond James & Assoc. Inc.
	 	 
	 	 
	 	By:	/s/ Marguerite Shoro
	 	Name:  	Marguerite Shoro
	 	Title:  	Authorized Signer/Custodian
	 	 
	 	 
	 	 
	 	/s/ Sandra K. McRee
	 	Sandra K. McRee

 

 

[Signature Page to Ninth Amendment to Note and
Warrant Purchase Agreement]

 

    	 

    	 

    

	 	INVESTORS:
	 	 
	 	/s/ Stephen Berkley
	 	Stephen Berkley
	 	 
	 	 
	 	/s/ Alexandra Berkley
	 	Alexandra Berkley
	 	 
	 	 
	 	/s/ Steven B. Epstein
	 	Steven B. Epstein
	 	 
	 	 
	 	/s/ Deborah L. Epstein
	 	Deborah L. Epstein
	 	 
	 	 
	 	/s/ Jason Peter Epstein
	 	Jason Peter Epstein
	 	 
	 	 
	 	/s/ Gregory Harris Epstein
	 	Gregory Harris Epstein
	 	 
	 	 
	 	/s/ David Epstein
	 	David Epstein
	 	 
	 	 
	 	/s/ Juliann Martin
	 	Juliann Martin
	 	 
	 	 
	 	/s/ Jason Thompson
	 	Jason Thompson

 

 

	 	Thompson Family Investments, LLC
	 	 
	 	By:	/s/ Jason Thompson
	 	Name:	Jason Thompson
	 	Title:	Manager

 

 

[Signature Page to Ninth Amendment to Note and
Warrant Purchase Agreement]

 

    	 

    	 

    

	 	INVESTORS:
	 	 
	 	/s/ Irwin Leiber
	 	Irwin Leiber
	 	 
	 	 
	 	/s/ Joseph P. Healey
	 	Joseph P. Healey
	 	 
	 	 
	 	/s/ Arthur B. Cohen
	 	Arthur B. Cohen

 

 

	 	SJ2, LLC
	 	 
	 	 
	 	By:	/s/ Michael Mashaal
	 	Name:  	Michael Mashaal
	 	Title:  	Manager
	 	 
	 	 
	 	The Joseph P. Healey 2011 Family Trust
	 	 
	 	 
	 	By: 	/s/ Joseph L. Dowling
	 	Name: 	Joseph L. Dowling
	 	Title: 	Trustee
	 	 
	 	 
	 	Rockwell Holdings I, LLC
	 	 
	 	 
	 	By:	/s/ Matthew Bluhm
	 	Name: 	Matthew Bluhm
	 	Title: 	Managing Member

 

 

[Signature Page to Ninth Amendment to Note and
Warrant Purchase Agreement]

 

    	 

    	 

    

 

	 	INVESTORS:
	 	 
	 	PENSCO TRUST COMPANY LLC, not in its corporate capacity but solely as Custodian of the Individual Retirement Account of Jeffrey C. Lightcap
	 	 
	 	 
	 	By:	/s/ Cody Alford
	 	Name: 	Cody Alford
	 	Title: 	Authorized Signor

 

 

	 	/s/ Jeffrey C. Lightcap
	 	Jeffrey C. Lightcap

 

 

	 	Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Bradford C. Lightcap
	 	 
	 	 
	 	By:	/s/ Ira Schwartz
	 	Name: 	Ira Schwartz
	 	Title: 	Trustee
	 	 
	 	 
	 	Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Brian R. Lightcap
	 	 
	 	 
	 	By:	/s/ Ira Schwartz
	 	Name: 	Ira Schwartz
	 	Title: 	Trustee
	 	 
	 	 
	 	Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997 F/B/O Megan M. Lightcap
	 	 
	 	 
	 	By:	/s/ Ira Schwartz
	 	Name: 	Ira Schwartz
	 	Title: 	Trustee

 

 

[Signature Page to Ninth Amendment to Note and
Warrant Purchase Agreement]

 

    	 

    	 

    

ACKNOWLEDGED AND AGREED:

 

	CareView Communications, Inc., a Texas corporation	 
	 	 	 
	By:	/s/ Steven G. Johnson	 
	Name: 	Steven G. Johnson	 
	Title: 	President	 
	 	 	 
	 	 	 
	CareView Operations, LLC	 
	 	 	 
	By:	/s/ Steven G. Johnson	 
	Name: 	Steven G. Johnson	 
	Title: 	President	 

 

 

[Signature Page to Ninth Amendment to Note and
Warrant Purchase Agreement]

 

    	 

    	 

    

Exhibit 7(a)(1)

 

Form of Allonge No. 2 to 2011 Notes 

 

 

    	 

    	 

    

Exhibit 7(a)(2)

 

Form of Allonge No. 2 to 2012 Notes

 

    	 

    	 

    

Exhibit 7(b)

 

Form of Allonge No. 2 to 2014 Supplemental
Closing Notes 

 

 

    	 

    	 

    

Exhibit 7(c)

 

Form of Allonge No. 2 to Fifth Amendment
Supplemental Closing Notes 

 

    	 

    	 

    

Exhibit 7(d)

 

Form of Allonge No. 1 to Eighth Amendment
Supplemental Closing Notes 

 

    	 

    	 

    

Exhibit 7(e)

 

Form of Second Amendment to Subordination
and Intercreditor AgreementCareView Communications, Inc. 8-K

 

Exhibit 10.44 

 

HEALTHCOR
PARTNERS FUND, L.P.

 

ALLONGE
NO. 2 TO SENIOR SECURED CONVERTIBLE NOTE

(issued
April 21, 2011)

 

July
10, 2018

  

This
Allonge No. 2 to Senior Secured Convertible Note (this “Allonge”) shall be affixed to that certain Senior Secured
Convertible Note dated April 21, 2011 (as amended by Allonge No. 1 to Senior Secured Convertible Note dated June 26, 2015, the
“Note”), issued in the original principal amount of $9,316,000, made by CareView Communications, Inc., a Nevada
corporation (the “Company”) and payable to the order of HealthCor Partners Fund, L.P. (the “Holder”),
and shall become a permanent part thereof and shall amend the Note as provided herein.

 

1.

Amendment
to Maturity Date. The second sentence of Section 1 of the Note is hereby deleted and replaced with the following:

 

The
“Maturity Date” shall be the earlier to occur of (a) April 20, 2021 or (b) 120 calendar days following a written
demand for payment by the Holder to the Company; provided, that such written demand may not be given prior to the twelve
month anniversary of the date on which the obligations of the Company under the PDL Credit Agreement are repaid in full.

 

2.       

Amendment
to Interest Rate. Section 2(b) of the Note is hereby amended to add the following sentence at the end thereof:

 

“Notwithstanding
the foregoing, no Interest shall accrue on this Note from and after the payment of Interest on June 30, 2018.”

 

3.       

Amendment
to Payment Priorities. Section 2(f) of the Note is hereby amended and restated in its entirety as follows:

 

“(f) This
Note is one of a series of notes issued by the Company pursuant to the Purchase Agreement. Such Notes are referred to herein as
the “Notes,” and the holders thereof (including the Holder) are referred to herein as the “Investors.”
The Notes initially issued in calendar years 2011 and 2012 (including this Note, the “First Tranche Notes”)
are senior in right of payment to the Notes initially issued after calendar year 2012, as more fully set forth in the Purchase
Agreement. The right of an Investor to receive payments of Principal and Interest under this Note shall be pari passu with
the rights of the other Investors to receive payments of Principal and Interest under their respective First Tranche Notes,
and the Company covenants that any payments made by it with respect to the First Tranche Notes shall be made pro rata among
the Investors determined based on the ratio of the outstanding balance of Principal and Interest under each First Tranche
Note divided by the aggregate outstanding balance of Principal and Interest under all First Tranche Notes.  By the Holder’s
acceptance of this Note, the Holder agrees to the foregoing sentence.”

 

3.       

Amendment
to Conversion Right. The first sentence of Section 3(a) of the Note is hereby amended and restated as follows:

 

“At
any time on or after the Issuance Date, and through and including June 30, 2018, the Holder shall be entitled to convert any portion
of the outstanding and unpaid Conversion Amount (as defined below) into fully paid and nonassessable shares of Common Stock in
accordance with Section 3(c), at the Conversion Rate (as defined below); provided, that for the avoidance of doubt and
notwithstanding any provision in this Note to the contrary, the conversion right set forth in this Section 3 shall terminate as
of June 30, 2018.”

 

4.       

No
Further Amendments; Authorization to Affix to Note. Except as specifically amended hereby, the Note shall remain in full force
and effect. The Company hereby authorizes the Holder to affix this Allonge to the Note and it shall for all purposes henceforth
be part of the Note.

 

[signature
page follows]

 

    	 1

    	 

    

 

 

Exhibit 10.44 

 

IN
WITNESS WHEREOF, the Company has caused this Allonge to be executed by its officer thereunto duly authorized, as of the date first
above written.

 

	 	COMPANY:
	 	 
	 	CAREVIEW COMMUNICATIONS, INC.,

a Nevada corporation
	 	 
	 	 
	 	By:	/s/ Steven Johnson	 
	 	Name:	Steven Johnson
	 	Title:	Chief Executive Officer

 

	AGREED
AND ACCEPTED:	 
	 	 
	HOLDER:	 
	 	 
	HEALTHCOR
PARTNERS FUND, L.P.	 
	By:	HealthCor
Partners Management, L.P., as Manager	 
	By:	HealthCor
Partners Management, G.P., LLC, as General Partner	 
	 	 
	 	 
	By:	/s/ Jeffrey Lightcap	 	 
	Name:	Jeffrey
Lightcap	 
	Title:	Senior
Managing Director	 

 

[Signature Page to Allonge No. 2 to CareView
Communications, Inc. Secured Convertible Note

issued April 21, 2011 (HCP Fund)]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]